How is Cerebrolysin used?

107.6 mg of Cerebrolysin at 215.2 mg/mL is 0.5 mL, the 50 mark on a U-100 syringe.

Every vial at a glance. Pick a cell to draw it on the syringe.

Each row is a concentration; units are the dose over the concentration, times 100, on a U-100 syringe.
ConcentrationDraw per dose
215.2 mg/mL215.2 mg/mL: 53.8 mg is 0.25 mL, the 25 mark, 107.6 mg is 0.5 mL, the 50 mark, 215.2 mg is 1 mL, the 100 mark

The maker's leaflet gives 20 to 50 mL a day for 10 to 21 days in stroke, and 10 to 30 mL a day in vascular dementia and Alzheimer's disease, 5 days weekly for 4 weeks in 2 to 4 cycles a year, by IV infusion or IV or IM injection.1

How Cerebrolysin is supplied and measured

Pack listedStrength
10 ampoules of 1 mL2215.2 mg/mL
5 ampoules of 5 mL2215.2 mg/mL
5 ampoules of 10 mL2215.2 mg/mL

The listing is a Polish pharmacy's, and the maker's product information gives 215.2 mg of Cerebrolysin concentrate per mL of aqueous solution.3 The maker gives doses of 10 to 50 mL a day,1 more than a U-100 syringe holds, so the mg figures and syringe marks below are arithmetic on the concentration,3 not sourced doses.

107.6 mg of Cerebrolysin at 215.2 mg/mL is 0.5 mL, the 50 mark on a U-100 syringe.

107.6 mg of Cerebrolysin at 215.2 mg/mL is 0.5 mL, the 50 mark on a U-100 syringe.

Route, volume and dilution

The maker's leaflet gives IV injection up to 10 mL undiluted and IM injection up to 5 mL undiluted, each slowly over 3 minutes, immediately after breaking the ampoule.1 The maker's handbook gives infusion as 10 to 50 mL diluted to at least 100 mL total volume with saline, Ringer solution or 5% glucose solution, infused within 15 to 60 minutes.4 The maker's dosage leaflet gives the infusion time as within 15 minutes.1 It says intramuscular injections into different muscles or at different times may be given to reach a daily dose above 5 mL, and that no direct comparable data for IV versus IM administration are available.4 The leaflet says not to mix Cerebrolysin with balanced amino acid solutions, vitamins or cardiovascular medicinal products.1

What the maker and the trials give per day

The maker's dosage leaflet gives 20 to 50 mL a day for 10 to 21 days in stroke and 20 to 50 mL a day for 7 to 30 days in traumatic brain injury.1 In vascular dementia and Alzheimer's disease it gives 10 to 30 mL a day in 2 to 4 cycles a year, one cycle being 5 days weekly for 4 weeks.1

TrialDose and schedulePeopleLength
CASTA, stroke (Heiss)530 mL IV daily against saline placebo, both arms with aspirin 100 mg daily1070 patients with acute ischaemic hemispheric stroke10 days, followed up to 90 days
Alzheimer's dose-ranging trial (Alvarez)610, 30 or 60 mL IV infusions or placebo, 5 days per week for the first 4 weeks, then two IV infusions per week for 8 weeksTwo hundred and seventy-nine patients with mild to moderate Alzheimer's disease24 weeks
Alzheimer's 28-week trial (Ruether)730 mL IV infusions or placebo, 5 days per week for 4 weeks, repeated after a 2-month therapy-free intervalOne hundred and forty-nine patients with mild to moderate Alzheimer's disease28 weeks
Vascular dementia trial (Guekht)8IV once daily (20 mL in 250 mL saline solution) for 4 weeks on five consecutive days per week, repeated after a two-month treatment-free interval, against saline placebo, both arms with 100 mg acetylsalicylic acid daily242 enrolled with vascular dementia24 weeks (two 4-week courses)
CAPTAIN I (Poon) and II (Muresanu), brain injury91050 mL daily for 10 days, then two cycles of 10 mL daily for 10 days each, against saline placebo, added to standard care46 and 142 enrolled, with moderate-to-severe traumatic brain injury10 days, then two 10-day cycles; CAPTAIN II endpoint at day 90

In the Alvarez trial, at week 24 the 10 mL dose significantly improved cognition on the ADAS-cog and global function, while the 30 and 60 mL doses significantly improved the global outcome but not cognition.6 The CAPTAIN registry entry gives 50 mL a day for 10 days, repeated one and two months later if the extended Glasgow Outcome Scale score is under 7 on day 30.11 No logged Cerebrolysin figure is shown for Milligram.

How Cerebrolysin is stored

The maker's leaflet gives storage at room temperature not above 25°C, without freezing.1 The handbook adds protection from light in the carton, a shelf life of 5 years, and letting refrigerated solution warm to room temperature before opening.4 It says to remove the solution from the ampoule immediately before use, because microbes may grow once an ampoule is open, and to start an infusion immediately after dilution, giving no time for which a diluted solution keeps.4

Frequently asked questions

Is there a US label for Cerebrolysin?

A search of DailyMed found no Cerebrolysin label. The maker's product information is based on the Austrian summary of product characteristics, says more on posology and storage is in that document, and notes that the prescribing information in each country may vary.3

What is the subcutaneous dose of Cerebrolysin?

The searches found no subcutaneous dose in people: PubMed held only animal studies of it, no Cerebrolysin study on ClinicalTrials.gov listed it, and the maker's handbook names only IV infusion and IV or IM routes.

Does Cerebrolysin need reconstituting?

The maker's product information describes a solution for injection holding 215.2 mg of Cerebrolysin concentrate per mL in aqueous solution, with sodium hydroxide and water for injection as excipients.3 Neither the handbook nor the product information gives any reconstitution water.

References

  1. EVER Neuro Pharma. Dosage Recommendation. cerebrolysin.com
  2. mp.pl pharmacy listing. Cerebrolysin roztwór do wstrzykiwań i infuzji - działanie, dawkowanie, cena, refundacja | Medycyna Praktyczna. mp.pl
  3. EVER Neuro Pharma. A comprehensive overview of Cerebrolysin®. cerebrolysin.com
  4. EVER Neuro Pharma. Cerebrolysin Treatment Handbook. cerebrolysin.com
  5. PubMed. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. 2012. pubmed.ncbi.nlm.nih.gov
  6. PubMed. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. 2006. pubmed.ncbi.nlm.nih.gov
  7. PubMed. A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease. 2001. pubmed.ncbi.nlm.nih.gov
  8. ClinicalTrials.gov. NCT00947531: A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia. 2009. clinicaltrials.gov
  9. PubMed. Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I-a randomized, placebo-controlled, double-blind, Asian-Pacific trial. 2020. pubmed.ncbi.nlm.nih.gov
  10. PubMed. Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial. 2020. pubmed.ncbi.nlm.nih.gov
  11. ClinicalTrials.gov. NCT01606111: The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery. 2015. clinicaltrials.gov